Can an organic compound tame COVID-19 in High-Risk patients?

NCT ID NCT05785390

Terminated Disease control Sponsor: Novatek Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial is testing an organic compound called NP-101 in adults with mild-to-moderate COVID-19 who are at high risk of severe illness. The study aims to find the safest and most effective dose, and to see whether NP-101 can help patients recover faster and reduce the amount of virus in their bodies compared to a placebo. Participants will receive either NP-101 or an identical placebo, and researchers will monitor safety and recovery over the study period.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NP-101 (TQ Formula), an organically derived, GMP-manufactured product
What this could lead to: If successful, NP-101 could offer a new treatment option for high-risk COVID-19 patients, potentially speeding recovery and reducing viral load.
What could go wrong: This is an early-phase trial (IIa/IIb) with a small number of participants, so results may not confirm efficacy or safety. There is also a risk of side effects or no benefit compared to placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Locations

Clinical Trial Network

Houston, Texas, 77074, United States
L&A Morales Healthcare/ Enrique Villa, MD Principal Investigator

Miami, Florida, 33142, United States
Pearland Family Wellness Clinic

Pearland, Texas, 77584, United States
Research Network America

Berwyn, Illinois, 60402, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.